Inpatient Basal-Bolus Insulin Protocol

Dynamic Titration, NPO Management & Acute Glycaemic Clearances · v7.0
Master Workflow: Define the patient baseline, then select the required clinical pathway. Renal adjustments, Correction Scales (ISF), and U-500 conversion alerts (when TDD > 200 U/day) are generated automatically. Tube feed, TPN, peripartum and sick-day protocols are available under their respective groups.

1. Patient Baseline & Renal Status

2. Clinical Pathway

⚙ Action Profiles of Common Insulins

Insulin Type Onset Peak Duration
Rapid-Acting (Lispro, Aspart) 10-15 mins1-2 hours3-5 hours
Short-Acting (Regular / Actrapid) 30-60 mins1-2 hours6-8 hours
Intermediate (NPH / Insulatard) 1-2 hours4-8 hours12-18 hours
Long-Acting (Glargine / Lantus) 1-2 hoursPeakless20-24 hours
Ultra-Long (Degludec / Tresiba) 1-2 hoursPeakless> 42 hours
U-500 Regular (Concentrated) 30 mins4-8 hours13-24 hours (unique — behaves like a hybrid bolus + intermediate)

Crucial Timing of Insulin vs. Meals

  • Rapid-Acting (Lispro/Aspart/Glulisine): Give 10 to 15 mins before eating. (May give immediately after eating if oral intake is highly unpredictable).
  • Short-Acting (Regular): MUST be given 30 to 45 mins before the meal. Giving it at the time of eating causes a post-prandial spike (before the insulin peaks) followed by delayed hypoglycaemia.
  • Intermediate (NPH) / Premix: Give 30 mins before breakfast and dinner.
  • Basal (Glargine/Degludec): Can be given at any time of day, but must be given at the exact same time every day.

Clinical Diagnostics & Alerts

⚠ Hypoglycaemia Begets Hypoglycaemia Unawareness
Repeated hypoglycaemic events blunt the autonomic warning signs (sweating, palpitations, tremors). Patients may suddenly develop severe neuroglycopenia (confusion, seizures, coma) without any prior symptoms. Action: If unawareness is suspected, strictly avoid hypoglycaemia for 2 to 3 weeks by raising target GRBS to restore autonomic warning mechanisms.
Somogyi Effect (Rebound Hyperglycaemia): High morning GRBS caused by an undetected nocturnal hypoglycaemic event (usually around 3 AM) which triggers counter-regulatory hormones (glucagon, cortisol, epinephrine) to spike the sugar. Treatment: Decrease the night NPH/Premix dose or give a bedtime snack.
Dawn Phenomenon: High morning GRBS caused by a normal physiological surge of growth hormone and cortisol in the early morning hours, creating insulin resistance. 3 AM sugars will be normal or high. Treatment: Increase the night NPH/Premix or shift it closer to bedtime.
Rule of 15 for Hypoglycaemia: If GRBS < 70 mg/dL: Administer 15 grams of fast-acting carbohydrate (e.g., 3 tsp sugar in water, 1/2 cup juice). Recheck GRBS in exactly 15 minutes. Repeat if still < 70 mg/dL. Once > 70, follow with a complex carb snack to prevent recurrence.

Specialised Inpatient Scenarios

Tube Feed Insulin Strategy: Match the insulin profile to the feed delivery pattern. Continuous feeds: NPH q6h or basal q24h (each covering ~1 U per 10 to 15 g of carbohydrate). Bolus feeds: Regular insulin SC 30 min before each feed (1 U per 10 to 15 g). Cyclic / nocturnal feeds: NPH at feed start; stop / taper 1 h before feed ends to prevent post-feed hypoglycaemia. If the feed is interrupted unexpectedly > 2 h, start D10 IV at the prior feed rate until feed resumes.
TPN Insulin Rule: Add insulin directly to the TPN bag. Start at 0.1 U Regular per g of dextrose (e.g., 250 g dextrose → 25 U in bag). Add a separate SC sliding scale for breakthrough hyperglycaemia. Never use a separate IV insulin infusion alongside TPN — if TPN stops abruptly, profound hypoglycaemia results. If TPN must be stopped suddenly, run D10 IV at the prior TPN rate × 1 to 2 h.
U-500 Regular (Severe Insulin Resistance): Indicated when TDD > 200 U/day (or > 2 U/kg/day). U-500 is 5× more concentrated than U-100, so dose in volume units (e.g., 200 U of U-100 = 40 "volume units" of U-500). Dosing errors are catastrophic. Use only dedicated U-500 syringes or U-500 pens — never standard U-100 syringes. Endocrine consult mandatory. Avoid in ICU / critical illness (use U-100 infusion there).
Postpartum Insulin Cliff: Within 1 to 2 hours of placental delivery, insulin requirements drop by ~50% (loss of placental hPL, cortisol, oestrogen). Continuing pregnancy-era doses is the commonest cause of postpartum DKA in T1DM. Action: Reduce basal to 50% of pre-pregnancy TDD immediately. Breastfeeding reduces requirements by a further 10 to 20%. For GDM, most patients normalise within 24 to 48 h and can stop insulin entirely with monitoring.
Sick Day Rules (T1DM): NEVER stop basal insulin during illness, even when not eating. Counter-regulatory hormones raise insulin needs by 10 to 20% during febrile illness. Check ketones if GRBS > 250 mg/dL or if unwell with normal GRBS. Frequent correction doses (q3-4h) of Regular insulin. Hospitalise if vomiting plus moderate/large ketones — this is impending DKA.
Active Labour Glucose Target: Maintain capillary BG 70 to 110 mg/dL throughout labour using IV insulin infusion + D5NS at 100 to 125 mL/h. Tight intrapartum control reduces neonatal hypoglycaemia at delivery. Hourly capillary BG. For elective C-section: hold all SC insulin morning of surgery, use IV protocol until eating.
Abbreviations: GRBS (Glucometer Random Blood Sugar) · TDD (Total Daily Dose) · ISF (Insulin Sensitivity Factor) · ICR (Insulin-to-Carb Ratio) · RRP (Regular-Regular-Premix) · NPO (Nil Per Os) · NPH (Neutral Protamine Hagedorn) · TPN (Total Parenteral Nutrition) · U-500 (5× concentrated Regular insulin) · hPL (human Placental Lactogen) · GDM (Gestational Diabetes Mellitus) · DKA (Diabetic Ketoacidosis)
Algorithm References & Evidence Base
  1. American Diabetes Association. Standards of Care in Diabetes - 2025. Diabetes Care 2025;48(Suppl 1).
  2. Umpierrez GE et al. Randomised study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007;30(9):2181-2186.
  3. Riddle MC et al. The treat-to-target trial: randomised addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients (AT.LANTUS). Diabetes Care 2003;26(11):3080-3086.
  4. Roberts A et al. Management of hyperglycaemia and steroid therapy: a guideline from the Joint British Diabetes Societies (JBDS). Diabet Med 2018;35(8):1011-1017.
  5. McMahon MM, Nystrom E, Braunschweig C, et al. A.S.P.E.N. Clinical Guidelines: Nutrition Support of Adult Patients with Hyperglycemia. JPEN J Parenter Enteral Nutr 2013;37(1):23-36.
  6. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus. Obstet Gynecol 2018;132(6):e228-e248.
  7. Joint British Diabetes Societies for Inpatient Care. The Management of Diabetic Ketoacidosis in Adults (JBDS 02). JBDS-IP; 2023.
  8. Lane WS, Cochran EK, Jackson JA, et al. High-dose insulin therapy: Is it time for U-500 insulin? Endocr Pract 2009;15(1):71-79.
How to Cite This Tool

AMA Style:
Umakanth S. Inpatient Basal-Bolus Insulin Protocol. MEDiscuss. Published 2026. Accessed .

Vancouver Style:
Umakanth S. Inpatient Basal-Bolus Insulin Protocol [Internet]. MEDiscuss.org; 2026 [cited ]. Available from:

Category Therapeutic Pathways & Algorithms
Specialties Internal Medicine, Endocrinology